Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 3 3Phase 1/2 3Phase 2 2

Status

Withdrawn 1Terminated 1Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3

Conditions

Small Cell Lung Carcinoma 3Neoplasms 2Neoplasm Metastasis 1

Interventions

Cisplatin 726Carboplatin 609Paclitaxel 579Cyclophosphamide 516Radiotherapy 511Docetaxel 477Fluorouracil 454Gemcitabine 438Doxorubicin 383Capecitabine 361Dexamethasone 328Oxaliplatin 289pembrolizumab 283Leucovorin 283Bevacizumab 275Etoposide 272Vincristine 270Rituximab 246Prednisone 223Pemetrexed 217Cytarabine 205Drug Therapy 194Trastuzumab 176Irinotecan 174Methotrexate 171Lenalidomide 137Nivolumab 136Filgrastim 135Epirubicin 129Tamoxifen 128

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Interventional × rovalpituzumab tesirine × Clear all
NCT03033511 2021-07-29

MERU

AbbVie

Phase 3 Terminated
748 enrolled 13 charts
Thoracic

Neoplasms, Small Cell Lung Carcinoma

NCT03061812 2021-02-23

TAHOE

AbbVie

Phase 3 Completed
444 enrolled 16 charts
Thoracic

Neoplasm Metastasis, Small Cell Lung Carcinoma

NCT03334487 2018-12-26

Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer

AbbVie

Phase 3 Withdrawn
Thoracic

Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡